3,4-Dihydroxybenzylamine (hydrobromide)

3,4-Dihydroxybenzylamine hydrobromide (NSC 263475 hydrobromide) is an improved dopamine analog cytotoxic and inhibits DNA polymerase activity in melanoma cells[2]. 3,4-Dihydroxybenzylamine hydrobromide (NSC 263475 hydrobromide) displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity[2].

Product Specifications

CAS Number

[16290-26-9]

Product Name Alternative

NSC 263475 (hydrobromide)

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/3-4-dihydroxybenzylamine-hydrobromide.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

[H]Br.NCC1=CC(O)=C(O)C=C1

Molecular Formula

C7H10BrNO2

Molecular Weight

220.07

Precautions

H315, H319, H335

References & Citations

[1]FitzGerald GB, et al. 3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymerase.J Invest Dermatol. 1983 Feb;80 (2) :119-23.|[2]Prezioso JA1, et al.Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.Pigment Cell Res. 1990 Mar-Apr;3 (2) :49-54.|[3]Mlchael M. Wick, et al. 3,4-Dihydroxybenzylamine: Antitumor Activity Against A Dopamine Analog B16 Melanoma.